Value through Innovation27 July 2016

What is a lay summary?

To view this video in other translations click on the language below:
Chinese (simplified)
Chinese (traditional)
French
German
Italian
Japanese
Portuguese (Brazilian)
Spanish

Clinical Study Results

  • BUSCOFEN ® - Healthy
    Clinical Study Number 1024.7
    Study Indication Healthy
    Product BUSCOFEN ®
    Generic Name Ibuprofen
    Lab Code
    Clinical Phase I
    Study Title

    Bioequivalence of a fixed-dose combination tablet containing 200 mg ibuprofen and 30 mg pseudoephedrine HCl compared to RhinAdvil® (200 mg ibuprofen and 30 mg pseudoephedrine HCl) as a fixed-dose combination tablet administered in healthy male and female volunteers (open-label, randomised, single dose, two-way crossover, Phase I trial)

    Study Document
    Trial synopsis 1024.7_DR english
  • BUSCOFEN ® - Healthy
    Clinical Study Number 1024.3
    Study Indication Healthy
    Product BUSCOFEN ®
    Generic Name Ibuprofen
    Lab Code
    Clinical Phase I
    Study Title

    An open two-way cross-over study to evaluate the relative bioavailability of lbuprofen enantiomers after single p.o. administration of 200 mg syrup (T) compared with 200 mg standard Brufen® syrup (R).

    Study Document
    Trial synopsis 1024.3 english
  • BUSCOFEN ® - Healthy
    Clinical Study Number 1024.5
    Study Indication Healthy
    Product BUSCOFEN ®
    Generic Name Ibuprofen
    Lab Code
    Clinical Phase I
    Study Title

    Open-label, randomised, single dose, four-way crossover study to investigate the relative bioavailability of a 400 mg ibuprofen extrudate tablet compared to a 400 mg ibuprofen lysinate tablet (Dolormin extra®) and a 400 mg ibuprofen tablet (Brufen® 400 mg, Denmark), in fasted condition and after ingestion of a standardised meal in healthy male and female volunteers

    Study Document
    Trial synopsis 1024.5 english